The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Commercializing Biomarkers Market Research Report 2025
Synopsis
Biomarkers measure cellular, biochemical or molecular changes in human tissues, cells or fluids, and contribute to future diagnostics and treatment. The development of biomarkers is time consuming and expensive, requiring the involvement of industry from early stages to better direct the research.
The global Commercializing Biomarkers market was valued at US$ 21390 million in 2023 and is anticipated to reach US$ 29560 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
North American market for Commercializing Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Commercializing Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Commercializing Biomarkers include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers.
Report Scope
The Commercializing Biomarkers market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Commercializing Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Commercializing Biomarkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Commercializing Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Commercializing Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Biomarkers measure cellular, biochemical or molecular changes in human tissues, cells or fluids, and contribute to future diagnostics and treatment. The development of biomarkers is time consuming and expensive, requiring the involvement of industry from early stages to better direct the research.
The global Commercializing Biomarkers market was valued at US$ 21390 million in 2023 and is anticipated to reach US$ 29560 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
North American market for Commercializing Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Commercializing Biomarkers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Commercializing Biomarkers include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers.
Report Scope
The Commercializing Biomarkers market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Commercializing Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Commercializing Biomarkers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Commercializing Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Commercializing Biomarkers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Commercializing Biomarkers Market Overview
1.1 Product Overview and Scope of Commercializing Biomarkers
1.2 Commercializing Biomarkers Segment by Type
1.2.1 Global Commercializing Biomarkers Market Value Comparison by Type (2024-2030)
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Commercializing Biomarkers Segment by Application
1.3.1 Global Commercializing Biomarkers Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Others
1.4 Global Commercializing Biomarkers Market Size Estimates and Forecasts
1.4.1 Global Commercializing Biomarkers Revenue 2019-2030
1.4.2 Global Commercializing Biomarkers Sales 2019-2030
1.4.3 Global Commercializing Biomarkers Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Commercializing Biomarkers Market Competition by Manufacturers
2.1 Global Commercializing Biomarkers Sales Market Share by Manufacturers (2019-2024)
2.2 Global Commercializing Biomarkers Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Commercializing Biomarkers Average Price by Manufacturers (2019-2024)
2.4 Global Commercializing Biomarkers Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Commercializing Biomarkers, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Commercializing Biomarkers, Product Type & Application
2.7 Commercializing Biomarkers Market Competitive Situation and Trends
2.7.1 Commercializing Biomarkers Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Commercializing Biomarkers Players Market Share by Revenue
2.7.3 Global Commercializing Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Commercializing Biomarkers Retrospective Market Scenario by Region
3.1 Global Commercializing Biomarkers Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Commercializing Biomarkers Global Commercializing Biomarkers Sales by Region: 2019-2030
3.2.1 Global Commercializing Biomarkers Sales by Region: 2019-2024
3.2.2 Global Commercializing Biomarkers Sales by Region: 2025-2030
3.3 Global Commercializing Biomarkers Global Commercializing Biomarkers Revenue by Region: 2019-2030
3.3.1 Global Commercializing Biomarkers Revenue by Region: 2019-2024
3.3.2 Global Commercializing Biomarkers Revenue by Region: 2025-2030
3.4 North America Commercializing Biomarkers Market Facts & Figures by Country
3.4.1 North America Commercializing Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Commercializing Biomarkers Sales by Country (2019-2030)
3.4.3 North America Commercializing Biomarkers Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Commercializing Biomarkers Market Facts & Figures by Country
3.5.1 Europe Commercializing Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Commercializing Biomarkers Sales by Country (2019-2030)
3.5.3 Europe Commercializing Biomarkers Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Commercializing Biomarkers Market Facts & Figures by Country
3.6.1 Asia Pacific Commercializing Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Commercializing Biomarkers Sales by Country (2019-2030)
3.6.3 Asia Pacific Commercializing Biomarkers Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Commercializing Biomarkers Market Facts & Figures by Country
3.7.1 Latin America Commercializing Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Commercializing Biomarkers Sales by Country (2019-2030)
3.7.3 Latin America Commercializing Biomarkers Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Commercializing Biomarkers Market Facts & Figures by Country
3.8.1 Middle East and Africa Commercializing Biomarkers Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Commercializing Biomarkers Sales by Country (2019-2030)
3.8.3 Middle East and Africa Commercializing Biomarkers Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Commercializing Biomarkers Sales by Type (2019-2030)
4.1.1 Global Commercializing Biomarkers Sales by Type (2019-2024)
4.1.2 Global Commercializing Biomarkers Sales by Type (2025-2030)
4.1.3 Global Commercializing Biomarkers Sales Market Share by Type (2019-2030)
4.2 Global Commercializing Biomarkers Revenue by Type (2019-2030)
4.2.1 Global Commercializing Biomarkers Revenue by Type (2019-2024)
4.2.2 Global Commercializing Biomarkers Revenue by Type (2025-2030)
4.2.3 Global Commercializing Biomarkers Revenue Market Share by Type (2019-2030)
4.3 Global Commercializing Biomarkers Price by Type (2019-2030)
5 Segment by Application
5.1 Global Commercializing Biomarkers Sales by Application (2019-2030)
5.1.1 Global Commercializing Biomarkers Sales by Application (2019-2024)
5.1.2 Global Commercializing Biomarkers Sales by Application (2025-2030)
5.1.3 Global Commercializing Biomarkers Sales Market Share by Application (2019-2030)
5.2 Global Commercializing Biomarkers Revenue by Application (2019-2030)
5.2.1 Global Commercializing Biomarkers Revenue by Application (2019-2024)
5.2.2 Global Commercializing Biomarkers Revenue by Application (2025-2030)
5.2.3 Global Commercializing Biomarkers Revenue Market Share by Application (2019-2030)
5.3 Global Commercializing Biomarkers Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Commercializing Biomarkers Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Dako (Agilent Technologies)
6.2.1 Dako (Agilent Technologies) Corporation Information
6.2.2 Dako (Agilent Technologies) Description and Business Overview
6.2.3 Dako (Agilent Technologies) Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Dako (Agilent Technologies) Commercializing Biomarkers Product Portfolio
6.2.5 Dako (Agilent Technologies) Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Commercializing Biomarkers Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 BD
6.4.1 BD Corporation Information
6.4.2 BD Description and Business Overview
6.4.3 BD Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BD Commercializing Biomarkers Product Portfolio
6.4.5 BD Recent Developments/Updates
6.5 Abbott
6.5.1 Abbott Corporation Information
6.5.2 Abbott Description and Business Overview
6.5.3 Abbott Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Abbott Commercializing Biomarkers Product Portfolio
6.5.5 Abbott Recent Developments/Updates
6.6 Genesys Biolabs (20/20GeneSystems)
6.6.1 Genesys Biolabs (20/20GeneSystems) Corporation Information
6.6.2 Genesys Biolabs (20/20GeneSystems) Description and Business Overview
6.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers Product Portfolio
6.6.5 Genesys Biolabs (20/20GeneSystems) Recent Developments/Updates
6.7 Affymetrix
6.6.1 Affymetrix Corporation Information
6.6.2 Affymetrix Description and Business Overview
6.6.3 Affymetrix Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Affymetrix Commercializing Biomarkers Product Portfolio
6.7.5 Affymetrix Recent Developments/Updates
6.8 Agendia
6.8.1 Agendia Corporation Information
6.8.2 Agendia Description and Business Overview
6.8.3 Agendia Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Agendia Commercializing Biomarkers Product Portfolio
6.8.5 Agendia Recent Developments/Updates
6.9 ALMAC
6.9.1 ALMAC Corporation Information
6.9.2 ALMAC Description and Business Overview
6.9.3 ALMAC Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.9.4 ALMAC Commercializing Biomarkers Product Portfolio
6.9.5 ALMAC Recent Developments/Updates
6.10 Arrayit
6.10.1 Arrayit Corporation Information
6.10.2 Arrayit Description and Business Overview
6.10.3 Arrayit Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Arrayit Commercializing Biomarkers Product Portfolio
6.10.5 Arrayit Recent Developments/Updates
6.11 Biocartic
6.11.1 Biocartic Corporation Information
6.11.2 Biocartic Commercializing Biomarkers Description and Business Overview
6.11.3 Biocartic Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Biocartic Commercializing Biomarkers Product Portfolio
6.11.5 Biocartic Recent Developments/Updates
6.12 BG Medicine
6.12.1 BG Medicine Corporation Information
6.12.2 BG Medicine Commercializing Biomarkers Description and Business Overview
6.12.3 BG Medicine Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.12.4 BG Medicine Commercializing Biomarkers Product Portfolio
6.12.5 BG Medicine Recent Developments/Updates
6.13 KEGG EXPRESSION Database
6.13.1 KEGG EXPRESSION Database Corporation Information
6.13.2 KEGG EXPRESSION Database Commercializing Biomarkers Description and Business Overview
6.13.3 KEGG EXPRESSION Database Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.13.4 KEGG EXPRESSION Database Commercializing Biomarkers Product Portfolio
6.13.5 KEGG EXPRESSION Database Recent Developments/Updates
6.14 Thermo Fisher
6.14.1 Thermo Fisher Corporation Information
6.14.2 Thermo Fisher Commercializing Biomarkers Description and Business Overview
6.14.3 Thermo Fisher Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Thermo Fisher Commercializing Biomarkers Product Portfolio
6.14.5 Thermo Fisher Recent Developments/Updates
6.15 BGI
6.15.1 BGI Corporation Information
6.15.2 BGI Commercializing Biomarkers Description and Business Overview
6.15.3 BGI Commercializing Biomarkers Sales, Revenue and Gross Margin (2019-2024)
6.15.4 BGI Commercializing Biomarkers Product Portfolio
6.15.5 BGI Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Commercializing Biomarkers Industry Chain Analysis
7.2 Commercializing Biomarkers Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Commercializing Biomarkers Production Mode & Process
7.4 Commercializing Biomarkers Sales and Marketing
7.4.1 Commercializing Biomarkers Sales Channels
7.4.2 Commercializing Biomarkers Distributors
7.5 Commercializing Biomarkers Customers
8 Commercializing Biomarkers Market Dynamics
8.1 Commercializing Biomarkers Industry Trends
8.2 Commercializing Biomarkers Market Drivers
8.3 Commercializing Biomarkers Market Challenges
8.4 Commercializing Biomarkers Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
